Caribou Biosciences, Inc. Debt Securities, Available-for-sale, Amortized Cost
Caribou Biosciences, Inc. (CRBU) had Debt Securities, Available-for-sale, Amortized Cost of $318.56 million as of 2022-12-31, per its 10-Q filed 2023-05-09.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-05-09
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $318.56M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $367.66M.
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $391.91M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $413.64M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-12-31 | $318.56M 10-Q · filed 2023-05-09 |
| 2022-06-30 | $367.66M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $391.91M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $413.64M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |